Clark M Henderson1, Pamela L Lutsey2, Jeffrey R Misialek2, Thomas J Laha1, Elizabeth Selvin3, John H Eckfeldt4, Andrew N Hoofnagle5. 1. Department of Laboratory Medicine and. 2. Division of Epidemiology and Community Health. 3. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 4. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN; 5. Department of Laboratory Medicine and Department of Medicine, University of Washington, Seattle, WA; ahoof@u.washington.edu.
Abstract
BACKGROUND: Vitamin D deficiency is associated with poor bone health and other adverse health outcomes; however, the associations are greatly attenuated in black vs white individuals. One possible explanation for this attenuation is different concentrations of bioavailable vitamin D metabolites in plasma, which are estimated with equations that include the total concentration of vitamin D binding globulin (VDBG) and haplotype-specific dissociation constants. METHODS: We developed a method to quantify VDBG with LC-MS/MS that could also identify the haplotypes/isoforms of VDBG present. We validated the method according to recent recommendations for publications of biomarker studies. We determined serum VDBG concentrations in samples from the Atherosclerosis Risk in Communities cohort and compared the results with a widely used monoclonal immunoassay. RESULTS: With 10 μL of serum or plasma, the lower limit of quantification for the assay (<20% CV) was 71 μg/mL. The assay was linear from 62 to 434 μg/mL, with total imprecision of 7.3-9.0% CV at approximately 250 μg/mL. Significant hemolysis interfered with quantification. The identification of isoforms was 97% concordant with genotyping (κ coefficient). Method comparison with immunoassay revealed significant isoform-specific effects in the immunoassay. Mean concentrations (SD) of VDBG by mass spectrometry were similar in whites and blacks [262 (25) vs 266 (35) μg/mL, respectively; P = 0.43]. CONCLUSIONS: Validated mass spectrometric methods for the quantification of proteins in human samples can provide additional information beyond immunoassay. Counter to prior observations by immunoassay, VDBG concentrations did not vary by race.
BACKGROUND:Vitamin D deficiency is associated with poor bone health and other adverse health outcomes; however, the associations are greatly attenuated in black vs white individuals. One possible explanation for this attenuation is different concentrations of bioavailable vitamin D metabolites in plasma, which are estimated with equations that include the total concentration of vitamin D binding globulin (VDBG) and haplotype-specific dissociation constants. METHODS: We developed a method to quantify VDBG with LC-MS/MS that could also identify the haplotypes/isoforms of VDBG present. We validated the method according to recent recommendations for publications of biomarker studies. We determined serum VDBG concentrations in samples from the Atherosclerosis Risk in Communities cohort and compared the results with a widely used monoclonal immunoassay. RESULTS: With 10 μL of serum or plasma, the lower limit of quantification for the assay (<20% CV) was 71 μg/mL. The assay was linear from 62 to 434 μg/mL, with total imprecision of 7.3-9.0% CV at approximately 250 μg/mL. Significant hemolysis interfered with quantification. The identification of isoforms was 97% concordant with genotyping (κ coefficient). Method comparison with immunoassay revealed significant isoform-specific effects in the immunoassay. Mean concentrations (SD) of VDBG by mass spectrometry were similar in whites and blacks [262 (25) vs 266 (35) μg/mL, respectively; P = 0.43]. CONCLUSIONS: Validated mass spectrometric methods for the quantification of proteins in human samples can provide additional information beyond immunoassay. Counter to prior observations by immunoassay, VDBG concentrations did not vary by race.
Authors: Cassianne Robinson-Cohen; Leila R Zelnick; Andrew N Hoofnagle; Pamela L Lutsey; Gregory Burke; Erin D Michos; Steven J C Shea; Russell Tracy; David S Siscovick; Bruce Psaty; Bryan Kestenbaum; Ian H de Boer Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Song Yao; Chi-Chen Hong; Elisa V Bandera; Qianqian Zhu; Song Liu; Ting-Yuan David Cheng; Gary Zirpoli; Stephen A Haddad; Kathryn L Lunetta; Edward A Ruiz-Narvaez; Susan E McCann; Melissa A Troester; Lynn Rosenberg; Julie R Palmer; Andrew F Olshan; Christine B Ambrosone Journal: Am J Clin Nutr Date: 2017-04-19 Impact factor: 7.045
Authors: Casey M Rebholz; Morgan E Grams; Pamela L Lutsey; Andrew N Hoofnagle; Jeffrey R Misialek; Lesley A Inker; Andrew S Levey; Elizabeth Selvin; Chi-Yuan Hsu; Paul L Kimmel; Ramachandran S Vasan; John H Eckfeldt; Josef Coresh Journal: Am J Kidney Dis Date: 2015-10-23 Impact factor: 8.860
Authors: Clark M Henderson; Susan L Fink; Hanan Bassyouni; Bob Argiropoulos; Lindsay Brown; Thomas J Laha; Konner J Jackson; Raymond Lewkonia; Patrick Ferreira; Andrew N Hoofnagle; Julien L Marcadier Journal: N Engl J Med Date: 2019-03-21 Impact factor: 91.245
Authors: Adrienne Tin; Long Zhang; Michelle M Estrella; Andy Hoofnagle; Casey M Rebholz; Todd T Brown; Frank J Palella; Mallory D Witt; Lisa P Jacobson; Lawrence A Kingsley; Alison G Abraham Journal: AIDS Res Hum Retroviruses Date: 2017-09-05 Impact factor: 2.205
Authors: Clark M Henderson; Nicholas J Shulman; Brendan MacLean; Michael J MacCoss; Andrew N Hoofnagle Journal: Clin Chem Date: 2017-12-04 Impact factor: 8.327
Authors: Pamela L Lutsey; Christina M Parrinello; Jeffrey R Misialek; Andy N Hoofnagle; Clark M Henderson; Thomas J Laha; Erin D Michos; John H Eckfeldt; Elizabeth Selvin Journal: Clin Chem Date: 2016-09-30 Impact factor: 8.327